Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06397573 · ClinicalTrials.gov registry record · NA

Ablative Stereotactic MR-Guided Adaptive Reirradiation

A NA study of Abdominal Cancer and Pelvic Cancer, sponsored by Baptist Health South Florida.

Active
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT06397573 is a NA study of Abdominal Cancer and Pelvic Cancer that is active but no longer recruiting, run by Baptist Health South Florida. The registered enrollment target is 10 participants, below the 87-participant average among 7 other Abdominal Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06397573, a NA study of Abdominal Cancer and Pelvic Cancer, is active but no longer recruiting, sponsored by Baptist Health South Florida.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This research study will enroll people who have cancer in their abdomen or pelvis that was treated previously with radiation therapy. The purpose of this research study is to test the safety and possible harms of treating tumors in these regions with another round of radiation therapy, called reirradiation or "reRT." The researchers want to find out what effects (good and bad) reRT has in people with cancer in the abdomen and pelvis.

Interventions

  • RADIATION Reirradiation

Study Locations (1)

Florida

  • Miami Cancer Institute at Baptist Health South Florida - Miami

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-06-05
Est. Completion 2027-06
Phase NA

Sponsor

Baptist Health South Florida

40 total trials

What the Registry Record Tells You About NCT06397573

The ClinicalTrials.gov registry entry for NCT06397573 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 7 other Abdominal Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Abdominal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Reirradiation is the first listed.

NCT06397573 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06397573 about?

NCT06397573 is a clinical study titled "Ablative Stereotactic MR-Guided Adaptive Reirradiation". This research study will enroll people who have cancer in their abdomen or pelvis that was treated previously with radiation therapy. The purpose of this research study is to test the safety and possible harms of treating tumors in these regions with another round of radiation therapy, called reirra...

What is the current status of trial NCT06397573?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2024-06-05. Estimated completion is 2027-06.

What conditions does trial NCT06397573 study?

This clinical trial studies the following conditions: Abdominal Cancer, Pelvic Cancer.

What interventions are being tested in trial NCT06397573?

The interventions under investigation include: Reirradiation (RADIATION).

Who is sponsoring clinical trial NCT06397573?

This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06397573 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Abdominal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.